NovoCure's Q1 beat, Optune Lua momentum, and global expansion signal strong growth ahead. Find out why NVCR stock is a buy.

4月23日，全球肿瘤治疗领域迎来重大突破——美国生物技术公司 Novocure 宣布，创新疗法肿瘤电场治疗设备Optune ...

Discover why analysts are bullish on NovoCure Limited despite ongoing insider selling. Click for more on NVCR Q1 performance, ...

Celgene aims to boost the effectiveness of its novel drug marizomib for aggressive brain tumour glioblastoma (GBM) by asking patients to wear a special cap. Marketed by Novocure, the Optune ...

Optune Lua is now approved for use concurrently with immune checkpoint inhibitors or docetaxel in adult patients with metastatic NSCLC who have progressed on or after a platinum-based regimen CE ...

The treatments can be used together to extend the survival of glioblastoma patients. But the Optune device, which has a list price of $27,000 a month, is rarely used in Canada because the ...

Recognized revenue from Optune Lua ® in the quarter was $1.5 million, including $0.8 million from malignant pleural mesothelioma (MPM), and $0.7 million from metastatic non-small cell lung cancer ...

Optune Gio 1,608 prescriptions for Optune Gio for the treatment of glioblastoma were received in the quarter, a decrease of 1% from the same period in 2024. The U.S., Germany, France and Japan ...

Quarterly net revenues of $155 million, up 12% year-over-year, with 4,268 active patients on therapy as of March 31, 2025 Results from Phase 3 PANOVA-3 trial in pancreatic cancer accepted as ...

For the full year 2024, Novocure’s total net revenues were $605.2 million, reflecting a 19% growth from the previous year. This growth was largely driven by the successful launch of Optune Gio for ...

Enhanced tumor biology understanding, next-gen clinical trials, and device-based therapies have all contributed to a more comprehensive approach to GBM management. Optune is a standout innovation. As ...

Optune Lua received a CE Mark for treating metastatic NSCLC, used with immune checkpoint inhibitors or docetaxel after progression on a platinum-based regimen. The phase 3 LUNAR trial showed ...